San Diego, CA-based Illumina Inc., a leader in DNA sequencing, announced the opening of its permanent facility, Illumina Solutions Center in Bangalore, India.
The Center features a fully equipped laboratory housing the latest Next-Generation Sequencing and array technologies, and it is fully resourced with field applications and service engineers to offer the company’s partners and customers broad genomics capabilities. Additionally, the Center will support Illumina’s growing number of channel partners in the region by providing training and education to increase local technical expertise and access to genomics.
Illumina will continue to collaborate with New Delhi-based Premas Life Sciences, its channel partner in India for 16 years to grow the genomics market in India, the world’s most populous country.
“Expanding Illumina’s presence in India allows the company to collaborate and be part of a vibrant biotech ecosystem with skilled labor, strong research and development resources, and supportive government policies,” said Gretchen Weightman, senior vice president, Asia Pacific, Middle East & Africa. “In our 25th anniversary year, it’s a very exciting time to be growing our physical presence in India to drive access and the further adoption of genomics to transform human health, particularly in oncology and infectious disease.”
Globally, tuberculosis is one infectious disease of concern. India accounts for nearly 30% of those cases. Illumina has supported TB surveillance over the last seven years in India through the FIND Seq&Treat project, which aims to increase uptake of next-generation sequencing for affordable, scalable, and rapid TB drug-susceptibility testing.
Last updated: December 26th, 2025
